Today, the Integrated Regulatory Review Service (IRRS) mission was officially opened at ARPANSA. Officials emphasised the mission, reviewing Australia’s nuclear protection and radiation safety regulatory framework, shows international openness and transparency and a commitment to improvement.
On 19 September 2018, at the International Atomic Energy Agency (IAEA) General Conference in Vienna, ARPANSA’s Deputy Chief Executive Officer, Gillian Hirth, alongside the Deputy Chairman of the Board of the Dutch Authority for Nuclear Safety and Radiation Protection (ANVS), Marco Brugmans, signed a memorandum of understanding (MoU).
On 29 June 2018, the CEO of ARPANSA, Dr Carl-Magnus Larsson, issued the Australian Nuclear Science and Technology Organisation with a direction under section 41(1A) of the Australian Radiation Protection and Nuclear Safety Act 1998.
The International Commission on Non-Ionizing Radiation Protection has published draft guidelines for public consultation. ARPANSA is revising its Radiofrequency Standard and will consider the ICNIRP guidelines in this process.
Aircrew are exposed to elevated levels of cosmic radiation while flying at high altitudes. A recent study from the Harvard T.H. Chan School of Public Health in the United States found that the prevalence of certain cancers in flight attendants was higher than the general population.
An article published in the Daily Mail Australia on 18 June 2018, reports that using a mobile phone can be as damaging on your skin as being out in the sun. It is concerning that the exposure from smartphones has been compared to the same time spent in the sun.
Starting on Monday 4 June and continuing this week, ARPANSA, in collaboration with the International Atomic Energy Agency, hosts a Regional Training Course on Radiochemical Analysis of Marine Environmental Samples.
On 24-25 May 2018, ARPANSA and the International Atomic Energy Agency hosted an Asia-Pacific region workshop on the Establishment and Maintenance of a National Dose Registry for those who work with radiation as part of their jobs.
ARPANSA’s CEO, Dr Carl-Magnus Larsson has issued a licence to the Australian Nuclear Science and Technology Organisation (ANSTO) to operate the ANSTO Nuclear Medicine Molybdenum-99 (Mo-99) Facility (the ANM Facility).
On Monday 26 February 2018 a report by the CEO of ARPANSA, Dr Carl-Magnus Larsson, was tabled in Parliament addressing the radiation exposure of a worker at the Australian Nuclear Science and Technology Organisation (ANSTO) Health radiopharmaceuticals production facility at Lucas Heights.
A series of animal studies on mobile phone radiofrequency radiation and health have been conducted over two years by the United States Department of Health and Human Services National Toxicology Program.
ARPANSA respectfully acknowledges the Traditional Owners and Custodians of Country throughout Australia and their continuing connection to land, waters and community. We pay our respect to Aboriginal and Torres Strait Islander Peoples, their cultures, and to Elders past, present and emerging.